Amn Healthcare Announces Third Quarter 2026 Results

AMN Healthcare posted strong Q3 growth but forecasts a sharp revenue drop next quarter.

What the company is saying

AMN Healthcare Services, Inc. reports a robust third quarter, highlighting consolidated revenue of $717.3 million, up 13% year over year, and adjusted EBITDA of $93.6 million, up 63%. The company emphasizes outperformance versus guidance, attributing gains to travel nurse and allied businesses and a significant labor disruption reserve release. President and CEO Cary Grace frames the narrative around strengthened demand for travel nursing and allied staffing, improved recruiting efficiency, and ongoing progress in other segments. The release is candid about segment performance, noting double-digit volume growth in core businesses and a 15% year-over-year increase in search revenue, while acknowledging declines in the Physician and Leadership Solutions and Technology and Workforce Solutions segments. The tone is confident but measured, with forward-looking guidance for Q4 openly projecting a 10-12% revenue decline due to a sharp drop in labor disruption revenue. The company also details its cash position, debt, and capital allocation, including share repurchases.

What the data suggests

The Q3 2026 results show consolidated revenue of $717.3 million, a 13% year-over-year increase, and adjusted EBITDA of $93.6 million, up 63%. GAAP net income was $33.4 million, or $0.83 per diluted share, and adjusted EPS was $1.16, a 199% increase from the prior year. The Nurse and Allied Solutions segment drove growth with $460 million in revenue, up 27%, including $59 million from labor disruption, while the Physician and Leadership Solutions segment declined 4% to $171 million and Technology and Workforce Solutions fell 9% to $86 million. Gross margin improved to 31.9%, up 280 basis points, and operating margin was 7.0%. Cash and equivalents stood at $256 million, with total debt of $750 million and negative operating cash flow of $88 million for the quarter, mainly due to client deposit refunds. The company repurchased $8.4 million in shares at $33.50 each. Q4 guidance projects revenue of $655–$670 million, a 10–12% year-over-year decline, driven by labor disruption revenue dropping to $5 million from $124 million in Q4 2025. Segment guidance points to double-digit declines in Nurse and Allied Solutions and continued weakness in other areas. The data indicates strong recent execution but a near-term headwind as labor disruption events normalize.

Analysis

The announcement provides a detailed and transparent account of AMN Healthcare's Q3 2026 financial performance, with all key profitability metrics (net income, EBITDA, operating margin, gross margin, cash flow) disclosed alongside revenue and segment breakdowns. The majority of claims are realised and supported by hard numbers, with only a small portion of the release dedicated to forward-looking guidance for Q4 2026. The tone is positive but proportionate to the strong operational and financial results, including significant year-over-year growth in revenue, EBITDA, and EPS. There is no evidence of narrative inflation or exaggerated claims; the language is factual and avoids promotional overstatement. Capital expenditures and debt levels are disclosed, but there is no indication of a large new capital outlay paired with uncertain, long-dated returns. The guidance for Q4 is conservative, reflecting expected declines in some segments, and is presented with appropriate caution.

Risk flags

• ●A sharp projected decline in Q4 revenue, with guidance 10–12% below the prior year, poses a near-term earnings risk and may pressure margins and profitability as labor disruption revenue normalizes.
• ●Segment-level declines, particularly in Physician and Leadership Solutions (down 4% year over year) and Technology and Workforce Solutions (down 9%), suggest potential structural or competitive challenges that could persist beyond the immediate quarter.
• ●Negative operating cash flow of $88 million in Q3, attributed to refunding client deposits, highlights volatility in cash generation and could constrain flexibility if similar events recur.
• ●High debt levels, with $750 million outstanding, increase sensitivity to interest expense and may limit options if cash flow weakens further, especially as Q4 profitability is expected to contract.

Bottom line

AMN Healthcare delivered a strong Q3, with double-digit revenue and EBITDA growth led by travel nurse and allied staffing, but its Q4 guidance signals a sharp revenue and margin contraction as labor disruption revenue drops from $124 million to just $5 million. The company is transparent about the drivers, providing a clear breakdown by segment and a candid explanation for the expected downturn. While cash reserves are healthy at $256 million, negative operating cash flow and high debt warrant attention if softness persists. The core business remains profitable, but investors should expect near-term volatility as extraordinary labor disruption events subside. The most important takeaway is that Q3's strength is not sustainable into Q4, and the company's ability to stabilize core segment growth will be critical for future performance.

Announcement summary

(NYSE:AMN) AMN Healthcare Services, Inc. announced its third quarter 2026 financial results, reporting consolidated revenue of $717.3 million, a 13% increase from the prior year and a 7% increase from the prior quarter. Adjusted EBITDA for the quarter was $93.6 million, up 63% year over year, and GAAP net income was $33.4 million, or $0.83 per diluted share. Adjusted diluted EPS was $1.16, a 199% increase from the same quarter a year ago. Year-to-date revenue as of September 30, 2026, was $2,768.9 million, with gross profit of $803.8 million and net income of $116.7 million. The Nurse and Allied Solutions segment generated $460 million in revenue, up 27% year over year, with travel nurse staffing revenue up 19% and allied division revenue up 11% year over year. Labor disruption contributed $59 million in revenue for the quarter, compared to $25 million in the prior quarter and $12 million in the year-ago quarter. The Physician and Leadership Solutions segment reported revenue of $171 million, down 4% year over year, with locum tenens revenue at $138 million (down 5% year over year), interim leadership revenue down 5%, and search revenue up 15% year over year. Technology and Workforce Solutions segment revenue was $86 million, down 9% year over year, with language services revenue at $69 million (down 8%) and vendor management systems revenue at $15 million (down 11%). Consolidated gross margin was 31.9%, up 280 basis points year over year, and SG&A expenses were $149 million, or 20.8% of revenue. Income from operations was $51 million with an operating margin of 7.0%. Cash and cash equivalents at quarter-end totaled $256 million, with cash flow from operations at ($88 million) for the quarter and $285 million year to date. Capital expenditures were $10 million, and $8.4 million was used to repurchase 250,685 shares at an average price of $33.50. Total debt outstanding at quarter-end was $750 million, with nothing drawn on the revolving credit facility. For the fourth quarter of 2026, consolidated revenue is expected to be between $655 million and $670 million, with gross margin guidance of 25.7% to 26.2%, SG&A as a percentage of revenue at 21.2% to 21.7%, operating margin between (0.1%) and 0.5%, and adjusted EBITDA margin between 5.8% and 6.3%. Labor disruption revenue is expected to be $5 million in Q4 2026 compared to $124 million in Q4 2025. Nurse and Allied Solutions segment revenue is expected to be down 13-15% year over year, or up 13-15% excluding labor disruption. Physician and Leadership Solutions segment revenue is expected to be down 5-7% year over year, and Technology and Workforce Solutions segment revenue is projected to be down 8-10% year over year. Fourth quarter estimates include depreciation of $12.5 million, depreciation in cost of revenue of $2.5 million, amortization expense of $15.5 million, share-based compensation expense of $6 million, integration and other expenses of $2 million, interest expense of $8.5 million, marginal adjusted tax rate of 28%, and 40.1 million diluted average shares outstanding. Cary Grace, President and Chief Executive Officer, stated that demand for travel nursing and allied strengthened further, and the company is making progress on improvements in other segments. AMN Healthcare will host a conference call to discuss these results and outlook on November 5, 2026 at 5:00 p.m. Eastern Time.

Disagree with this article?